Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriam Labopin

Showing results (391-400 of 443) with videos related to

Pageof 45
Sort By:
Bone Marrow Transplantation|August 2, 2024
Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMTRama Al Hamed, Myriam Labopin, Depei Wu, et al.
Blood|December 14, 2011
Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party studyJan Styczynski, Adriana Balduzzi, Lidia Gil, et al.
Blood Cancer Journal|December 18, 2024
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFMFlorent Malard, Arthur Bobin, Myriam Labopin, et al.
Cancer Medicine|October 18, 2016
Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDSPatrice Chevallier, Myriam Labopin, Regis Peffault de La Tour, et al.
Blood Advances|August 26, 2018
Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP studySalyka Sengsayadeth, Katie S Gatwood, Ariane Boumendil, et al.
Haematologica|January 18, 2020
Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working PartyJoerg Henes, Maria Carolina Oliveira, Myriam Labopin, et al.
British Journal of Haematology|March 23, 2023
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remissionArnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, et al.
Bone Marrow Transplantation|October 19, 2022
Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TCPaul Chauvet, Annalisa Paviglianiti, Myriam Labopin, et al.
Bone Marrow Transplantation|July 16, 2025
Allogeneic hematopoietic cell transplantation for older patients with Philadelphia-positive acute lymphoblastic leukemia. A study by the Acute Leukemia Working Party of the EBMTSebastian Giebel, Myriam Labopin, Ryszard Swoboda, et al.
Haematologica|June 29, 2014
Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimenAnnalisa Ruggeri, Myriam Labopin, Maria Pia Sormani, et al.
Pageof 45

Showing results (391-400 of 443) with videos related to

Sort By:
Pageof 45
Bone Marrow Transplantation|August 2, 2024
Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMTRama Al Hamed, Myriam Labopin, Depei Wu, et al.
Blood|December 14, 2011
Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party studyJan Styczynski, Adriana Balduzzi, Lidia Gil, et al.
Blood Cancer Journal|December 18, 2024
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFMFlorent Malard, Arthur Bobin, Myriam Labopin, et al.
Cancer Medicine|October 18, 2016
Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDSPatrice Chevallier, Myriam Labopin, Regis Peffault de La Tour, et al.
Blood Advances|August 26, 2018
Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP studySalyka Sengsayadeth, Katie S Gatwood, Ariane Boumendil, et al.
Haematologica|January 18, 2020
Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working PartyJoerg Henes, Maria Carolina Oliveira, Myriam Labopin, et al.
British Journal of Haematology|March 23, 2023
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remissionArnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, et al.
Bone Marrow Transplantation|October 19, 2022
Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TCPaul Chauvet, Annalisa Paviglianiti, Myriam Labopin, et al.
Bone Marrow Transplantation|July 16, 2025
Allogeneic hematopoietic cell transplantation for older patients with Philadelphia-positive acute lymphoblastic leukemia. A study by the Acute Leukemia Working Party of the EBMTSebastian Giebel, Myriam Labopin, Ryszard Swoboda, et al.
Haematologica|June 29, 2014
Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimenAnnalisa Ruggeri, Myriam Labopin, Maria Pia Sormani, et al.
Pageof 45